SLN:NASDAQSilence Therapeutics Plc - American Depository Share Analysis

Silence Therapeutics (SLN) is trading at $10.49, comfortably above its 20‑day SMA (10.67) and 50‑day SMA (8.75), indicating a short‑term bullish bias, while the 200‑day SMA (6.85) confirms a longer‑term uptrend. The RSI sits at 51, suggesting neutral momentum, and the MACD histogram is marginally negative, hinting at a brief bearish wobble but not enough to overturn the overall bullish trend. Volume is accelerating, support sits at $8.91 and resistance at $12.19, and the stock has already gained 107% over the past six months, buoyed by strong investor sentiment (Fear/Greed Index 92.9 – “Extreme Greed”).
Fundamentally, SLN shows explosive revenue growth (nearly 200% YoY) and a robust gross margin of ~79%, yet it remains unprofitable with negative operating cash flow and a trailing EPS of –$1.62. The balance sheet is solid, with $70 M cash and minimal debt, but valuation multiples are extreme (price‑to‑sales >590×, P/B ~10×) and the forward PE is –26.9, reflecting high expectations for future approvals. The pipeline’s lead candidate, divesiran, is approaching pivotal Phase 2 readouts, which could catalyze further upside, while the company’s diversification into cardiovascular and obesity targets adds depth to its growth story.